Clinical trials
Cytokine Release Syndrome clinical trials
Below are recruiting cytokine release syndrome clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05306080RecruitingEarly Phase 1
Rescue treatment for CAR T side effects in adults
This trial tests a rescue medicine given to treat severe immune over-reactions that can happen after CAR T cell therapy, such as cytokine release syndrome and an HLH-like syndrome. It may help calm the immune response if you are already enrolled in a specific CAR T study.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06447376RecruitingPhase 1
Testing siltuximab before epcoritamab to prevent cytokine release syndrome
This trial tests whether giving siltuximab before epcoritamab can help prevent or reduce cytokine release syndrome (a possible side effect where the immune system overreacts). It is for people with certain types of non-Hodgkin lymphoma that have not responded well to at least two prior treatments.
Cleveland, OhioAges 18–65 - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT07499128Enrolling by invitation
Continuous temperature monitoring for cytokine release syndrome
This study tests a wearable device that continuously monitors your body temperature to detect cytokine release syndrome, a possible side effect of certain immunotherapies. The goal is to catch it early so you can get treatment faster.
Bethesda, MarylandAges 18–120 - NCT07390071Recruiting
Remote rehab program for CAR-T cell therapy patients
This trial tests a home-based rehabilitation program using phone or video sessions to help people with lymphoma or myeloma recover better after CAR-T cell therapy. It aims to improve physical function and quality of life during treatment.
Salt Lake City, UtahAges 21 years+ - NCT05146336Recruiting
CytoSorb registry for critically ill patients needing blood treatment
This registry collects information about critically ill patients who receive the CytoSorb 300 mL blood treatment. It may help doctors better understand when the treatment works best and when it should not be used.
KlagenfurtAges Any age - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07609940RecruitingPhase 4
Linvoseltamab plus tocilizumab for heavily treated multiple myeloma
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
Los Angeles, CaliforniaAges 18 years+ - NCT05905328RecruitingPhase 1/Phase 2
Drug to help prevent and treat cytokine release syndrome
This Phase 1/2 trial tests CTO1681 to help prevent and treat cytokine release syndrome (CRS) in people with DLBCL who are receiving CD19 CAR T-cell therapy. CRS is a potentially serious immune reaction that can happen after CAR T treatment, and this study aims to make that complication less severe or easier to manage.
Orange, CaliforniaAges 18 years+ - NCT07169487RecruitingPhase 1
Methylene Blue for Side Effects of Cancer Immunotherapy
This trial tests if methylene blue can help people who develop side effects called CRS or ICANS after treatments like CAR-T cells or bispecific antibodies. It is a first-in-human study to find a safe dose.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT06377059Recruiting
Early detection of complications during immunotherapy
This trial uses special equipment to watch for early side effects in people getting CAR T-cell therapy or bispecific antibodies for blood cancers, like lymphoma. It aims to catch problems early so they can be treated faster.
Copenhagen OAges 18 years+ - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Anchorage, AlaskaAges 18 years+ - NCT07106671RecruitingPhase 2
Siltuximab for side effects after CAR-T in multiple myeloma
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
TianjinAges 18 years+ - NCT06138587RecruitingPhase 1
NK cell therapy after stem cell transplant for high-risk blood cancers
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Boston, MassachusettsAges 18 years+
Hear when a new Cytokine Release Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cytokine release syndrome?
- Yes. Clin2 currently lists 15 recruiting cytokine release syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cytokine release syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cytokine release syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.